New Upfront Treatment Algorithm Emerges for Chronic Lymphocytic Leukemia

According to Susan M. O’Brien, MD, an expert in the treatment of chronic lymphocytic leukemia, novel agents and new data on patient subsets...

Breast Cancer

ASCO Adapts CCO Guideline on Selection of Optimal Adjuvant Therapies for HER2-Negative and HER2-Positive Breast Cancers

As reported in the Journal of Clinical Oncology by Neelima Denduluri, MD, and colleagues, ASCO has adapted a Cancer Care Ontario...

Supportive Care
Symptom Management

Scalp Cooling for Chemotherapy-Induced Alopecia Becoming Mainstream

Hair loss can be a devastating side effect of chemotherapy, but the recent U.S. Food and Drug Administration approval of the DigniCap...


More Top Stories

Kidney Cancer

David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients

Daniel F. Hayes, MD, FASCO, Leader in Translational Research, Begins Term as ASCO President

In 1995, Daniel F. Hayes, MD, FASCO, gathered with several other oncologists at a conference center in San Francisco to begin writing the first-ever ASCO guidelines on cancer treatment. He and his colleagues felt like pioneers scouting uncharted frontier. “I’ll never forget, that first hour or...


Melanoma MicroRNA Trafficking May Control Tumor Primary Niche Formation

Researchers at Tel Aviv University (TAU) may have unraveled the metastatic mechanism of melanoma. According to a paper published by Dror et al in Nature Cell Biology, scientists discovered that before spreading to other organs, a melanoma tumor sends out tiny vesicles containing molecules of...


Steven M. Horwitz, MD, on Sequencing New Agents in Relapsed Peripheral T-Cell Lymphoma

Colorectal Cancer

Anti–PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination With MEK Inhibition

Anti–PD-L1 (programmed death ligand 1) immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the European Society for Medical Oncology (ESMO) 18th World Congress on...

Pancreatic Cancer Action Network Appoints Four Leaders to Its Scientific and Medical Advisory Board

The Pancreatic Cancer Action Network has added four leaders from across the country to its Scientific and Medical Advisory Board. 

“Members of the Pancreatic Cancer Action Network Scientific and Medical Advisory Board have committed their careers to change the course of a deadly and complex...

Study Finds More Nodes Should Be Examined to Rule Out Node-Negative Disease in Papillary Thyroid Cancer

The proportion of patients with papillary thyroid cancer identified as having node-negative disease decreased substantially with an increased number of lymph nodes examined, according to an analysis of data from the National Cancer Database. Robinson and colleagues, of Duke University, reported...

Breast Cancer

Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes

Julienne Bower, PhD, Named Professor of Psychobiology in Cousins Center for Psychoneuroimmunology at UCLA

The Cousins Center for Psychoneuroimmunology at the University of California, Los Angeles (UCLA) Semel Institute for Neuroscience and the UCLA Jonsson Comprehensive Cancer Center (JCCC) announced that Julienne Bower, PhD, Co-Director of the JCCC Patients and Survivors Program, Professor of...


Influence of Patients’ Side-Effect Expectations on Outcome of Endocrine Treatment for Breast Cancer

A study of women receiving hormone therapies such as tamoxifen as part of their treatment for breast cancer found that the number and seriousness of side effects they experienced were influenced by their expectations. The study, published by Nestoriuc et al in Annals of Oncology, found that women...

click me